Recombinant human CD22 protein (ab50033)
Key features and details
- Expression system: CHO cells
- Purity: > 95% SDS-PAGE
- Active: Yes
- Suitable for: SDS-PAGE, Functional Studies
Description
-
Product name
Recombinant human CD22 protein
See all CD22 proteins and peptides -
Biological activity
Determined by its ability to inhibit the proliferation of Raji cells. The expected ED50 for this effect is 10-17 μg/mL.
-
Purity
> 95 % SDS-PAGE.
Greater than 98% by SDS-PAGE gel and HPLC analyses. Endotoxin level is less than 0.1 ng per µg (1EU/µg). -
Expression system
CHO cells -
Protein length
Protein fragment -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Sequence
SKWVFEHPET LYAWEGACVW IPCTYRALDG DLESFILFHN PEYNKNTSKF DGTRLYESTK DGKVPSEQKR VQFLGDKNKN CTLSIHPVHL NDSGQLGLRM ESKTEKWMER IHLNVSERPF PPHIQLPPEI QESQEVTLTC LLNFSCYGYP IQLQWLLEGV PMRQAAVTST SLTIKSVFTR SELKFSPQWS HHGKIVTCQL QDADGKFLSN DTVQLNVKHT PKLEIKVTPS DAIVREGDSV TMTCEVSSSN PEYTTVSWLK DGTSLKKQNT FTLNLREVTK DQSGKYCCQV SNDVGPGRSE EVFLQVQYAP EPSTVQILHS PAVEGSQVEF LCMSLANPLP TNYTWYHNGK EMQGRTEEKV HIPKILPWHA GTYSCVAENI LGTGQRGPGA ELDVQYPPKK VTTVIQNPMP IREGDTVTLS CNYNSSNPSV TRYEWKPHGA WEEPSLGVLK IQNVGWDNTT IACARCNSWC SWASPVALNV QYAPRDVRVR KIKPLSEIHS GNSVSLQCDF SSSHPKEVQF FWEKNGRLLG KESQLNFDSI SPEDAGSYSC WVNNSIGQTA SKAWTLEVLY APRRLRVSMS PGDQVMEGKS ATLTCESDAN PPVSHYTWFD WNNQSLPHHS QKLRLEPVKV QHSGAYWCQG TNSVGKGRSP LSTLTVYYSP ETIGRR -
Amino acids
22 to 686
-
Specifications
Our Abpromise guarantee covers the use of ab50033 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
Applications
SDS-PAGE
Functional Studies
-
Form
Lyophilized -
Concentration information loading...
Preparation and Storage
-
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
This product is an active protein and may elicit a biological response in vivo, handle with caution.
-
ReconstitutionReconstitute in water to a concentration of 0.1-1.0 mg/ml
General Info
-
Alternative names
- B cell receptor CD22 precursor
- B lymphocyte cell adhesion molecule
- B-cell receptor CD22
see all -
Function
Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules. -
Tissue specificity
B-lymphocytes. -
Sequence similarities
Belongs to the immunoglobulin superfamily. SIGLEC (sialic acid binding Ig-like lectin) family.
Contains 6 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 Ig-like V-type (immunoglobulin-like) domain. -
Domain
Contains 4 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases. -
Post-translational
modificationsPhosphorylation of Tyr-762, Tyr-807 and Tyr-822 are involved in binding to SYK, GRB2 and SYK, respectively. Phosphorylation of Tyr-842 is involved in binding to SYK, PLCG2 and PIK3R1/PIK3R2.
Phosphorylated on tyrosine residues by LYN. -
Cellular localization
Cell membrane. - Information by UniProt
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (0)
ab50033 has not yet been referenced specifically in any publications.